^
    Apply
    BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (DUET-1) (NCT05120271)
    Phase 1/2
    Sotio Biotech Inc.
    Recruiting
    Last update posted :
    01/11/2024
    Initiation :
    05/18/2022
    Primary completion :
    04/01/2026
    Completion :
    12/01/2041
    EGFR • ALK • BRCA • GPC3
    |
    EGFR mutation • ALK translocation • BRCA mutation • GPC3 expression • GPC3 overexpression
    |
    cyclophosphamide • BOXR1030